TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Processa Pharmaceuticals ( (PCSA) ).
On July 18, 2025, Processa Pharmaceuticals held its Annual Meeting of Shareholders where at least one-third of the voting power was represented. During the meeting, shareholders voted on four key proposals: the election of six directors, the issuance of shares upon exercise of Series A and B Warrants, the appointment of Cherry Bekaert, LLP as the independent accounting firm for 2025, and an advisory vote on executive compensation. All proposals were approved.
The most recent analyst rating on (PCSA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Average Trading Volume: 18,372,906
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.68M
Find detailed analytics on PCSA stock on TipRanks’ Stock Analysis page.